

MINI-REVIEW

DNA Methylation Biomarkers for Nasopharyngeal Carcinoma: Diagnostic and Prognostic Tools

Wei Jiang*, Rui Cai, Qiu-Qiu Chen

Abstract

Nasopharyngeal carcinoma (NPC) is a common tumor in southern China and south-eastern Asia. Effective strategies for the prevention or screening of NPC are limited. Exploring effective biomarkers for the early diagnosis and prognosis of NPC continues to be a rigorous challenge. Evidence is accumulating that DNA methylation alterations are involved in the initiation and progression of NPC. Over the past few decades, aberrant DNA methylation in single or multiple tumor suppressor genes (TSGs) in various biologic samples have been described in NPC, which potentially represents useful biomarkers. Recently, large-scale DNA methylation analysis by genome-wide methylation platform provides a new way to identify candidate DNA methylated markers of NPC. This review summarizes the published research on the diagnostic and prognostic potential biomarkers of DNA methylation for NPC and discusses the current knowledge on DNA methylation as a biomarker for the early detection and monitoring of progression of NPC.

Keywords: DNA methylation - nasopharyngeal carcinoma - biomarker - diagnosis - prognosis

Asian Pac J Cancer Prev, 16 (18), 8059-8065

Introduction

Nasopharyngeal carcinoma (NPC) is one of the most prevalent malignancies in southern China and south-eastern Asia. In southern China, the incidence rate is about 25-50 per 100,000 person years (Jeannel et al., 1999; McDermott et al., 2001; Wei and Sham, 2005). Despite considerable advances in NPC treatment, local recurrence or distant metastasis is observed frequently. The main challenge of NPC management remains a lack of effective biomarkers for developing more precise diagnostic, prognostic, treatment and prevention approaches (Heng et al., 1999; Hong et al., 2000; Ayan et al., 2003).

To date, abundant evidence convincingly demonstrated that aberrant epigenetic silencing of many tumor suppressor genes (TSGs), cellular functional genes and micro-RNAs (miRNAs) affect the normal cell growth and development (Esteller, 2007; Lujambio et al., 2008), which leads to various human malignancies (Belinsky et al., 1998; Mittag et al., 2006), that has been recognized as a common and early event in human cancers (Jones, 1996; Baylin and Herman, 2000). Of particular interest, the patterns of DNA methylation of normal tissues are distinct from those of tumor tissues, DNA methylation as a potential biomarker for diagnosis, prognosis, personalized therapy and disease management is just beginning to emerge. Recently, investigators have employed specific sets of methylated genes served as biomarkers for clinical practice in several types of cancer, such as lung (Koga et al., 2011), melanoma (You et al., 2010), and breast (Ramos

et al., 2010).

Like other types of cancers, NPC is associated with multiple genetic mutations and epigenetic aberrations (Lo and Huang, 2002; Lo et al., 2004). Studies have suggested that aberrant DNA methylation at the promoter CpG islands underlie the development and progression of NPC (Tao and Chan, 2007; Razak et al., 2010). In addition, growing evidence demonstrates that many genes are predominantly silenced by DNA methylation in NPC epithelial cells (Li et al., 2011a; Bruce et al., 2015). Identification of differential DNA methylation genes could contribute to the understanding of pathogenetic mechanisms and develop the available biomarkers to diagnose NPC early and optimize and personalize treatment for NPC.

Here, we detail the the current knowledge of DNA methylation biomarkers in terms of the diagnosis and prognosis of NPC.

Overview of research on DNA methylation and NPC

Over the past decade, many studies have specifically explored DNA methylation in NPC, and a large variety of genes with aberrant methylation (including the different pathways involved in carcinogenesis) have been reported

Earlier studies specifically assessed DNA methylation as either “present” or “absent” in a single gene or multiple genes. For instance, Lo and colleagues (Lo et al., 2002) reported that hypermethylation of a single gene *EDNRB* was detected in 19/21 (90.5%) primary tumors, whereas no methylation was found in normal nasopharyngeal

epithelia. Liu and colleagues (Liu et al., 2003) revealed that the BLU promoter region occurred hypermethylation in 74% of primary NPC tumors, whereas non-neoplastic nasopharyngeal tissue exhibited low methylation. From multiple-gene studies, Kwong and colleagues (Kwong et al., 2002) detected the prevalence of several genes methylation in NPC tumors including RARbeta2 (80%), DAP-kinase (76%), p16 (46%), p15 (17%), p14 (20%), and MGMT (20%), respectively. More recently, Yanatatsaneejit P and colleagues (Yanatatsaneejit et al., 2008) examined the methylation status of eight genes and higher frequencies of CCNA1 (48%), RARRES1 (51%), and HRASLS (17%), respectively, were found in NPC tumors. Significant differences among numerous the studied DNA methylation were scored both in the NPC and control tissues.

Detailed mechanistic studies that further elucidated biologic roles in NPC suggested that transcriptional inactivation of different TSGs by promoter hypermethylation is associated with many important cellular processes involved in tumorigenesis. Several reports have provided convincing evidence that UCHL1, WIF1, RASSF1A, FEZF2, LOX, Kank1 and RRAD are frequently inactivated by promoter methylation in NPC (Chow et al., 2004; Lin et al., 2006; Li et al., 2010; Mo et al., 2012; Shu et al., 2013; Sung et al., 2014; Luo et al., 2015). Restoration of the expression of these genes after demethylation always suppressed NPC cell growth, colony formation and apoptosis of NPC cells, as well as inhibiting their migration and invasion. Similarly to TSGs, silencing of miRNA by hypermethylation in NPC has shown its important involvement in various factors during carcinogenesis. For instance, restorations of miR-148a, miR31, miR34c and miR24 expressions inhibit cell growth and migration in NPC cells by targeting different downstream genes (Cheung et al., 2014; Li et al., 2014a;

Wang et al., 2014; Li et al., 2015b).

In addition, DNA methylation of TSGs were found to involved in multiple biological pathways during carcinogenesis and progression. It was recently reported that hypermethylated gene ADAMTS8 plays a promoting role in NPC progression by triggering EGFR-MEK-ERK signaling (Choi et al., 2014) Similarly, highly methylated gene ROR2 participated in the negative regulation of cell functions through suppressing β -catenin and AKT pathway (Li et al., 2014c). Tao and colleagues also revealed that gene methylation disrupts Wnt signaling, MAPK signaling, regulation of the actin cytoskeleton, Hedgehog signaling and TGF- β signaling pathways in NPC using microarray screening methods (Li et al., 2015a).

Analyses of DNA methylation not only provides the opportunity for understanding the molecular pathogenesis of the disease but can also be used to develop new potential new markers for diagnosis, prognosis and prediction of NPC.

DNA methylation as a potential diagnostic and prognostic markers of NPC

Due to the early occurrence and stability of DNA methylation, analysis of DNA methylation status has been suggested as a useful markers for the early detection and for prediction of outcome of multiple types of cancer (Delpu et al., 2013). DNA methylation is strongly associated with NPC, and hypermethylated DNA has great potential to become a biomarker for the early detection and prognosis of NPC. (Figure 1)

Marks for NPC Diagnosis

In 1996, Lo et al.(Lo et al., 1996) firstly reported high methylation level of p16 in NPC xenograft, cell line




Figure 1. DNA Methylation Can Potentially Serve as a Bomarker for the Early Detection and Prognosis of Nasopharyngeal Carcinoma (NPC). NP: nasopharyngeal; M&T: mouth and throat; MSP: methylation-specific polymerase chain reaction; MS-HRM: methylation-sensitive high-resolution melting.

Table 1. Summary of genes shown to be hypermethylated in nasopharyngeal carcinoma

Biomarker	Type of Sample	Method	Range of Methylation frequency	Marker Function	Reference
p16	NPC primary tumor biopsies	MSP	23-66%	diagnosis	(Ayadi et al., 2008; Challouf et al., 2012; Tian et al., 2013)
	NP brushing		46.40%		(Tong et al., 2002)
	NP swabs		17%		(Chang et al., 2003b)
	M&T rinsing fluid		17%		(Chang et al., 2003b)
	Plasma		42%		(Wong et al., 2004)
RASSF1A	NPC primary tumor biopsies	MSP	46-67%	diagnosis	(Chang et al., 2003b; Wong et al., 2003b)
	NP brushing		39.30%		(Tong et al., 2002)
	NP swabs		33%		
	M&T rinsing fluid		37%		
DAP-kinase	NPC primary tumor biopsies	MSP	75%-77%	diagnosis	(Wong et al., 2002; Chang et al., 2003b)
	NPC cell lines		80%		(Tong et al., 2002)
	NP brushing		50.00%		
	NP swabs		63%		
	M&T rinsing fluid		50%		
	Plasma		20%		(Wong et al., 2004)
CDH1	NPC primary tumor biopsies	MSP	50%	diagnosis	(Wong et al., 2003b)
	Plasma		46%		(Wong et al., 2004)
E-cadherin	NPC primary tumor biopsies	MSP	52% -65%	diagnosis	(Chang et al., 2003b; Tsao et al., 2003; Ran et al., 2011)
	NPC cell lines		100%		(Ran et al., 2011)
	NP swabs		27%		(Chang et al., 2003b)
	M&T rinsing fluid		43%		(Chang et al., 2003b)
HIN-1	NPC primary tumor biopsies	MSP	77%	diagnosis	(Wong et al., 2003a)
	NPC cell lines		100%		
	nasopharyngeal swabs		46%		
	throat-rinsing fluids		19%		
	Plasma		18%		
	buffy coats of peripheral blood		46%		
MGMT	NPC primary tumor biopsies	MSP	28%	diagnosis	(Wong et al., 2003b)
MLH1	NPC primary tumor biopsies	MSP	40%	diagnosis	(Wong et al., 2003b)
p15	NPC primary tumor biopsies	MSP	50-80%	diagnosis	(Chang et al., 2003b; Wong et al., 2003b)
	NP swabs		53%		
	M&T rinsing fluid		40%		
	Plasma		20%		
RIZ1	NPC paraffin and/or brushing	MSP	56.60%	diagnosis	(Chang et al., 2003a; Hutajulu et al., 2011)
THBS1	NPC primary tumor biopsies	MSP	50%	diagnosis	(Wong et al., 2003b)
TP73	NPC primary tumor biopsies	MSP	20%	diagnosis	(Wong et al., 2003b)
CHFR	NPC primary tumor biopsies	MSP	61.1% (22/36)	diagnosis	(Cheung et al., 2005)
	NPC cell lines		100%		
GADD45G	NPC primary tumor biopsies	MSP	73% (8/11)	diagnosis	(Ying et al., 2005)
TIG1	NPC primary tumor biopsies	MSP	90.7% (39/43)	diagnosis	(Kwong et al., 2005a)
CRBPs	NPC primary tumor biopsies	MSP	54.2%- 87.8%	diagnosis	(Kwong et al., 2005b)
DLC1	NPC primary tumor biopsies	MSP	79% (31/39)	diagnosis	(Peng et al., 2006)
	NPC paraffin and/or brushing	MSP	77%		(Hutajulu et al., 2011)
	NPC (endemic and sporadic types)		89% (64/72)		(Seng et al., 2007)
LTF	NPC primary tumor biopsies	MSP	63.6% (21/33)	diagnosis	(Yi et al., 2006)
PCDH10	NPC primary tumor biopsies	MSP	82%	diagnosis	(Ying et al., 2006)
CDH13	NPC primary tumor biopsies	MSP	89.7% (52/58)	diagnosis	(Sun et al., 2007)
	NPC cell lines		20% (1/5)		
	NPC xenografts		100% (2/2)		
BRD7	NPC primary tumor biopsies	MSP	100%	diagnosis	(Liu et al., 2008)
	Matched blood samples		100%		
IRF8	NPC primary tumor biopsies	MSP	78%	diagnosis	(Lee et al., 2008)
	NPC cell lines		100%		
14-3-3 sigma	NPC primary tumor biopsies	MSP	84%	prognosis	(Yi et al., 2009)
	NPC cell lines		100%		
LARS2	NPC primary tumor biopsies	MSP	64% (23/36)	diagnosis	(Zhou et al., 2009)
DAB2	NPC primary tumor biopsies	MSP	72% (33/46)	diagnosis	(Tong et al., 2010)
TFPI-2	NPC primary tumor biopsies	MSP	88.6% (62/70)	diagnosis	(Wang et al., 2010)
	NPC cell lines		66.7% (4/6)		
CADM1	NPC paraffin and/or brushing	MSP	69.80%	diagnosis	(Hutajulu et al., 2011)
CDH4	NPC primary tumor biopsies	MSP	94.30%	diagnosis	(Du et al., 2011)
	NPC cell lines		100%		
CHFR	NPC paraffin and/or brushing	MSP	58.50%	diagnosis	(Hutajulu et al., 2011)
LTF	NPC cell lines		100% (7/7)	diagnosis	(Zhang et al., 2011)
Myocardin	NPC primary tumor biopsies	MSP	73.8% (48/65)	diagnosis	(Chen et al., 2011)
	NPC cell lines		4 of 5 (80%)		
NOR1	NPC primary tumor biopsies	MSP	61.9% (13/21)	diagnosis	(Li et al., 2011b)
	NPC cell lines		100% (4/4)		
WIF1	NPC paraffin and/or brushing	MSP	61.20%	diagnosis	(Hutajulu et al., 2011)
PCDH8	NPC primary tumor biopsies	MSP	85.3% (35/41)	diagnosis	(He et al., 2012)
	NPC cell lines		100% (5/5)		
RRAD	NPC primary tumor biopsies	MSP	74.3% (26/35)	diagnosis	(Mo et al., 2012)
CACNA2D3	NPC primary tumor biopsies	MSP	100% (5/5)	diagnosis	(Wong et al., 2013)
	NPC cell lines		100% (3/3)		
CDK10	NPC primary tumor biopsies	MSP	52.50%	diagnosis	(You et al., 2013)
DLEC1	Cell-free circulating DNA	MSP	25.00%	diagnosis	(Tian et al., 2013)
FEZF2	NPC primary tumor biopsies	MSP	75.5% (37/49)	diagnosis	(Shu et al., 2013)
	nasal swab		75% (12/16)		
SOX11	NPC primary tumor biopsies	MSP	67.4% (29/43)	diagnosis, prognosis	(Zhang et al., 2013)
UCHL1	Cell-free circulating DNA	MSP	64.90%	diagnosis	(Tian et al., 2013)
TTC40	NPC primary tumor biopsies	MSP	71.12% (32/45)	diagnosis	(Ayadi et al., 2014)
LOX	NPC primary tumor biopsies	MSP	85.7% (42/49)	diagnosis	(Sung et al., 2014)
	Nose swab		18.75% (3/16)		
miR-148a	NPC primary tumor biopsies	Bisulfite sequencing	53-97%	diagnosis	(Li et al., 2014a)
PTEN	NPC primary tumor biopsies	MSP	82.2% (37/45)	diagnosis	(Li et al., 2014b)
	NPC cell lines		80% (4/5)		
WWOX	NPC primary tumor biopsies	MSP	56.9% (37/65)	diagnosis	(Yang et al., 2014)
CYB5R2	NPC primary tumor biopsies	MSP	84% (42/50)	diagnosis	(Xiao et al., 2014)
	NPC cell lines		100% (6/6)		
ECRG4	NPC primary tumor biopsies	MSP	72.5% (29/40)	diagnosis	(You et al., 2015)
	Peripheral blood samples from the NPC patients		57.5% (23/40)		
PCDH20	NPC primary tumor biopsies	MSP	78.4% (40/51)	diagnosis	(Chen et al., 2015)
	NPC cell lines		80% (4/5)		
ITGA9	NPC primary tumor biopsies	MSP	56%	diagnosis	(Nawaz et al., 2015a)

MSP : methylation-specific polymerase chain reaction; M&T: mouth and throat; NP: nasopharyngeal

and primary tumors. Several subsequent studies using methylation-specific polymerase chain reaction (MSP) approaches to investigate the promoter methylation profile of p16 found methylation frequencies to be 23-66% in primary undifferentiated NPC (Ayadi et al., 2008; Challouf et al., 2012; Tian et al., 2013), 46.4% in nasopharyngeal (NP) brushings (Tong et al., 2002), and 42% in plasma DNA (Wong et al., 2004). There was a perfect concordance in methylation among corresponding samples. The results demonstrated that the methylation level in p16 was a potential diagnostic tool for the differential diagnosis between benign NP tissue and malignant NP tumors.

Another example of the potential use of hypermethylated DNA as a biomarker was the involvement of the methylated gene RASSF1A in the early detection of NPC. Lo et al. (Lo et al., 2001) used MSP analyses to investigate hypermethylation of promoter regions of RASSF1A in nasopharyngeal primary tumors, xenografts, and cell lines for the first time. Other reports also presented the methylation frequency of RASSF1A promoters to be as high as 39.3% in nasopharyngeal brushings, 46%-67% in primary undifferentiated NPC, 33% in nasopharyngeal swabs, 37% in mouth and throat (M&T) rinsing fluid, respectively (Chang et al., 2003b; Wong et al., 2003b). From these efforts, it is clear that this molecular event is an early and important marker of NPC.

In the past decade, a multitude of studies demonstrated that other classical TSGs undergo hypermethylation in various biologic samples of NPC, including RRAD, DAP-kinase, CDH13, E-cad, TIG1, CHFR, DAB2, Myocardin, TFPI-2 and CDH4 and so on (Chang et al., 2003b; Tsao et al., 2003; Cheung et al., 2005; Kwong et al., 2005a; Sun et al., 2007; Tong et al., 2010; Wang et al., 2010; Chen et al., 2011; Du et al., 2011; Mo et al., 2012), thereby rendering their potential as alternative surrogate markers for the early diagnosis. We have summarized some examples of putative biomarkers in Table 1.

However, single epigenetic biomarkers are not sufficiently sensitive to detect early NPC accurately in tissue or body fluids, specific gene-methylation signatures have been suggested to improve sensitivity (Nawaz et al., 2015b). Hutajulu et al. applied quantitative profiling of DNA methylation in 10 TSGs in nasopharyngeal brushings and corresponding NPC paraffin-embedded tissue. The study found that combined analyses of five methylation markers (RASSF1A, p16, WIF1, CHFR and RIZ1) provided good discrimination between NPC and non-NPC with detection rate of 98% (Hutajulu et al., 2011). Myriam et al. used quantitative MSP to investigate promoter hypermethylation of 18 TSGs in NPC cell lines and NPC tumors biopsies. Authors suggested that combinatorial analyses of methylation of three genes (PGP9.5, KIF1A and DLEC) would detect NPC early with 84% sensitivity and 92% specificity (Loyo et al., 2011). In other methylation signature reports, the methylation level of four-gene marker (CDKN2A, DLEC1, DAPK1 and UCHL1) could early predict NPC with the highest sensitivity and specificity (Tian et al., 2013). A panel of four methylated genes (RASSF1A, WIF1, DAPK1 and RAR β 2) in combination with an EBV DNA marker significantly increased the prevalence of detection at an

early stage and local recurrence in NPC (Yang et al., 2015).

With recent developments in methods of high-throughput screening, several studies have evaluated genome-wide methylation profiling in NPC. Tao and colleagues using a whole-genome methylation platform newly identified hypermethylated genes SFRP1, 2 and 5, DACT1, DACT2 and DKK3 in NPC cell lines and primary tumors and suggested their potential value as biomarkers for NPC detection (Li et al., 2015a). Another genome-wide study in NPC demonstrated that the top 500 hypermethylated regions were frequently located at 6p21.3 in NPC. This region contains several important genes which could be used as biomarkers for NPC detection (Dai et al., 2015). Recently, our group also took a global methylation approach (the Illumina HumanMethylation450 BeadChip) to reveal both hyper- and hypomethylation alterations are common events in NPC tumor tissues. As a result, 2173 CpG sites with methylation level change ≥ 0.2 (1880 hypermethylated, 293 hypomethylated) were identified ($P < 0.05$), as well as use of potential markers for early diagnosis in NPC (Jiang et al., 2015).

The studies mentioned above provide strong evidence that tumor promoter-specific hypermethylation is closely related with the development of NPC, and suggest DNA methylation biomarker that combines high sensitivity and specificity could be used for the early detection of NPC.

Marks for NPC Prognosis

DNA methylation profiles was shown with abilities to better defined the prognoses of numerous cancers (Ramos et al., 2010; You et al., 2010; Koga et al., 2011). Emerging research supports the notion that detection of aberrantly methylated genes in NPC can serve as biomarkers for the prognosis. In comparison, methylation of 14-3-3 sigma correlates with metastasis to lymph node and distant metastasis (Yi et al., 2009). WIF-1 methylation has been found to be associated with the tumor, node, and metastasis (TNM) classification ($p = 0.003$) and age ($p = 0.014$) (Fendri et al., 2010). In primary NPC tumors, clinical studies have revealed that aberrant promoter methylation of the three genes (RASSF1A, RAR β 2 and DAPK) are significantly associated with the lymph-node involvement ($p < 0.0001$). In addition, hypermethylation of RASSF1A was found to be correlated with age at the diagnosis ($p = 0.047$) and T stage ($p = 0.037$), whereas the RAR β 2 hypermethylation was associated with histological type ($p = 0.011$) (Fendri et al., 2009).

Latterly, our group examined the methylation level of paraffin-embedded specimens with NPC and provide reasonable assurance that the 6-hypermethylated gene panel (WIF1, UCHL1, RASSF1A, CCNA1, TP73 and SFRP1) was an independent prognostic factor in large sample size. The study revealed that NPC with high methylation level is associated with poorer survival and may increase the therapeutic options for patients diagnosed with NPC (Jiang et al., 2015).

Clearly, the identification of new effective prognosis biomarkers for NPC will likely contribute to predict clinical outcomes and improved patient-tailored treatment. However, panels of candidate methylated-genes remain

to be validated in the prospective study.

Targeting DNA methylation for epigenetic therapy in NPC

Epigenetic changes are reversible, making DNA methylation a potential target for anticancer therapies. During the past decade, a growing number of drugs targeting DNA methylation have been developed, for example, azacytidine (5-azacytidine, 5-Aza-CR), and decitabine (5-aza-2'-deoxycytidine, 5-Aza-CdR). These agents have been used as single agents or combined with other anticancer therapies and validated in multiple clinical trials to reduce global DNA methylation in vivo. In particular, trials on hematologic malignancies have shown higher response rates. Among preclinical studies for NPC, decitabine decreased survival of NPC cell lines (Li et al., 2011b; Zhang et al., 2013; Luo et al., 2015) and azacytidine enhanced the radiosensitivity of NPC cells by promoting cell apoptosis (Jiang et al., 2014). Moreover, decitabine treatment reactivated the methylated gene ECRG4 and enhanced chemosensitivity to cisplatin in NPC cells (You et al., 2015). However, until recently, no clinical trials have been the process to shown an association between the level of induced demethylation and clinical response in patients with NPC.

Conclusion

NPC continues to be a major public-health problem in the China and and south-eastern Asia. However, a lack of effective biomarkers for early detection and monitoring of NPC progression contributes to its adverse outcomes. After more than a decade of studies, DNA methylation, with characteristics of high stability and easy evaluation, has been shown to be a high-potential tool with great sensitivity and specificity in the diagnosis and prognosis of NPC, which will extend our ability to improve NPC management. Further high-powered studies with perspective clinical data are required to establish the role of DNA methylation for the diagnosis and prognosis of NPC.

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (No. 81560443), the Natural Science Foundation of Guangxi Zhuang Autonomous Region (No.2013GXNSFBA019155), the Guangxi Medical Scientific Experiment Center Open Fund (GK2014-TKF04), and the Scientific Research and Technology Development Program of Guilin (No.20110119-1-3).

References

Ayadi W, Allaya N, Frikha H, et al (2014). Identification of a novel methylated gene in nasopharyngeal carcinoma: TTC40. *Biomed Res Int*, **2014**, 691742.
 Ayadi W, Karray-Hakim H, Khabir A, et al (2008). Aberrant methylation of p16, DLEC1, BLU and E-cadherin gene promoters in nasopharyngeal carcinoma biopsies from Tunisian patients. *Anticancer Res*, **28**, 2161-7.

Ayan I, Kaytan E, Ayan N (2003). Childhood nasopharyngeal carcinoma: from biology to treatment. *Lancet Oncol*, **4**, 13-21.
 Baylin SB, Herman JG (2000). DNA hypermethylation in tumorigenesis: epigenetics joins genetics. *Trends Genet*, **16**, 168-74.
 Belinsky SA, Nikula KJ, Palmisano WA, et al (1998). Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. *Proc Natl Acad Sci U S A*, **95**, 11891-6.
 Bruce JP, Yip K, Bratman SV, et al (2015). Nasopharyngeal Cancer: Molecular Landscape. *J Clin Oncol*, **33**, 3346-55.
 Challouf S, Ziadi S, Zaghoudi R, et al (2012). Patterns of aberrant DNA hypermethylation in nasopharyngeal carcinoma in Tunisian patients. *Clin Chim Acta*, **413**, 795-802.
 Chang HW, Chan A, Kwong DL, et al (2003a). Detection of hypermethylated RIZ1 gene in primary tumor, mouth, and throat rinsing fluid, nasopharyngeal swab, and peripheral blood of nasopharyngeal carcinoma patient. *Clin Cancer Res*, **9**, 1033-8.
 Chang HW, Chan A, Kwong DL, et al (2003b). Evaluation of hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharyngeal carcinoma patient. *Int J Cancer*, **105**, 851-5.
 Chen F, Mo Y, Ding H, et al (2011). Frequent epigenetic inactivation of Myocardin in human nasopharyngeal carcinoma. *Head Neck*, **33**, 54-9.
 Chen T, Long B, Ren G, et al (2015). Protocadherin20 acts as a tumor suppressor gene: epigenetic inactivation in nasopharyngeal carcinoma. *J Cell Biochem*, **116**, 1766-75.
 Cheung CC, Chung GT, Lun SW, et al (2014). miR-31 is consistently inactivated in EBV-associated nasopharyngeal carcinoma and contributes to its tumorigenesis. *Mol Cancer*, **13**, 184.
 Cheung HW, Ching YP, Nicholls JM, et al (2005). Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation. *Mol Carcinog*, **43**, 237-45.
 Choi GC, Li J, Wang Y, et al (2014). The metalloprotease ADAMTS8 displays antitumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation. *Mol Cancer Res*, **12**, 228-38.
 Chow LS, Lo KW, Kwong J, et al (2004). RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma. *Int J Cancer*, **109**, 839-47.
 Dai W, Cheung AK, Ko JM, et al (2015). Comparative methylome analysis in solid tumors reveals aberrant methylation at chromosome 6p in nasopharyngeal carcinoma. *Cancer Med*.
 Delpu Y, Cordelier P, Cho WC, et al (2013). DNA methylation and cancer diagnosis. *Int J Mol Sci*, **14**, 15029-58.
 Du C, Huang T, Sun D, et al (2011). CDH4 as a novel putative tumor suppressor gene epigenetically silenced by promoter hypermethylation in nasopharyngeal carcinoma. *Cancer Lett*, **309**, 54-61.
 Esteller M (2007). Cancer epigenomics: DNA methylomes and histone-modification maps. *Nat Rev Genet*, **8**, 286-98.
 Fendri A, Khabir A, Hadri-Guiga B, et al (2010). Epigenetic alteration of the Wnt inhibitory factor-1 promoter is common and occurs in advanced stage of Tunisian nasopharyngeal carcinoma. *Cancer Invest*, **28**, 896-903.
 Fendri A, Masmoudi A, Khabir A, et al (2009). Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma. *Cancer Biol Ther*, **8**, 444-51.
 He D, Zeng Q, Ren G, et al (2012). Protocadherin8 is a functional tumor suppressor frequently inactivated by promoter

- methylation in nasopharyngeal carcinoma. *Eur J Cancer Prev*, **21**, 569-75.
- Heng DM, Wee J, Fong KW, et al (1999). Prognostic factors in 677 patients in Singapore with nondisseminated nasopharyngeal carcinoma. *Cancer*, **86**, 1912-20.
- Hong MH, Mai HQ, Min HQ, et al (2000). A comparison of the Chinese 1992 and fifth-edition International Union Against Cancer staging systems for staging nasopharyngeal carcinoma. *Cancer*, **89**, 242-7.
- Hutajulu SH, Indrasari SR, Indrawati LP, et al (2011). Epigenetic markers for early detection of nasopharyngeal carcinoma in a high risk population. *Mol Cancer*, **10**, 48.
- Jeannel D, Bouvier G, Hubert A (1999). Nasopharyngeal carcinoma: An epidemiological approach to carcinogenesis. *Cancer Surveys*, **33**, 125-55.
- Jiang W, Li YQ, Liu N, et al (2014). 5-Azacytidine enhances the radiosensitivity of CNE2 and SUNE1 cells in vitro and in vivo possibly by altering DNA methylation. *PLoS One*, **9**, 93273.
- Jiang W, Liu N, Chen XZ, et al (2015). Genome-wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma. *Mol Cancer Ther*.
- Jones PA (1996). DNA methylation errors and cancer. *Cancer Res*, **56**, 2463-7.
- Koga T, Takeshita M, Yano T, et al (2011). CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer. *Int J Cancer*, **128**, 1009-17.
- Kwong J, Lo KW, Chow LS, et al (2005a). Silencing of the retinoid response gene TIG1 by promoter hypermethylation in nasopharyngeal carcinoma. *Int J Cancer*, **113**, 386-92.
- Kwong J, Lo KW, Chow LS, et al (2005b). Epigenetic silencing of cellular retinol-binding proteins in nasopharyngeal carcinoma. *Neoplasia*, **7**, 67-74.
- Kwong J, Lo KW, To KF, et al (2002). Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. *Clin Cancer Res*, **8**, 131-7.
- Lee KY, Geng H, Ng KM, et al (2008). Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas. *Oncogene*, **27**, 5267-76.
- Li HP, Huang HY, Lai YR, et al (2014a). Silencing of miRNA-148a by hypermethylation activates the integrin-mediated signaling pathway in nasopharyngeal carcinoma. *Oncotarget*, **5**, 7610-24.
- Li J, Gong P, Lyu X, et al (2014b). Aberrant CpG island methylation of PTEN is an early event in nasopharyngeal carcinoma and a potential diagnostic biomarker. *Oncol Rep*, **31**, 2206-12.
- Li L, Tao Q, Jin H, et al (2010). The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. *Clin Cancer Res*, **16**, 2949-58.
- Li L, Ying J, Tong X, et al (2014c). Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting beta-catenin and AKT signaling but frequently methylated in common carcinomas. *Cell Mol Life Sci*, **71**, 2179-92.
- Li L, Zhang Y, Fan Y, et al (2015a). Characterization of the nasopharyngeal carcinoma methylome identifies aberrant disruption of key signaling pathways and methylated tumor suppressor genes. *Epigenomics*, **7**, 155-73.
- Li LL, Shu XS, Wang ZH, et al (2011a). Epigenetic disruption of cell signaling in nasopharyngeal carcinoma. *Chin J Cancer*, **30**, 231-9.
- Li W, Li X, Wang W, et al (2011b). NOR1 is an HSF1- and NRF1-regulated putative tumor suppressor inactivated by promoter hypermethylation in nasopharyngeal carcinoma. *Carcinogenesis*, **32**, 1305-14.
- Li YQ, Ren XY, He QM, et al (2015b). MiR-34c suppresses tumor growth and metastasis in nasopharyngeal carcinoma by targeting MET. *Cell Death Dis*, **6**, 1618.
- Lin YC, You L, Xu Z, et al (2006). Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines. *Biochem Biophys Res Commun*, **341**, 635-40.
- Liu H, Zhang L, Niu Z, et al (2008). Promoter methylation inhibits BRD7 expression in human nasopharyngeal carcinoma cells. *BMC Cancer*, **8**, 253.
- Liu XQ, Chen HK, Zhang XS, et al (2003). Alterations of BLU, a candidate tumor suppressor gene on chromosome 3p21.3, in human nasopharyngeal carcinoma. *Int J Cancer*, **106**, 60-5.
- Lo KW, Cheung ST, Leung SF, et al (1996). Hypermethylation of the p16 gene in nasopharyngeal carcinoma. *Cancer Res*, **56**, 2721-5.
- Lo KW, Huang DP (2002). Genetic and epigenetic changes in nasopharyngeal carcinoma. *Semin Cancer Biol*, **12**, 451-62.
- Lo KW, Kwong J, Hui AB, et al (2001). High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. *Cancer Res*, **61**, 3877-81.
- Lo KW, To KF, Huang DP (2004). Focus on nasopharyngeal carcinoma. *Cancer Cell*, **5**, 423-8.
- Lo KW, Tsang YS, Kwong J, et al (2002). Promoter hypermethylation of the *EDNRB* gene in nasopharyngeal carcinoma. *Int J Cancer*, **98**, 651-5.
- Loyo M, Brait M, Kim MS, et al (2011). A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. *Int J Cancer*, **128**, 1393-403.
- Lujambio A, Calin GA, Villanueva A, et al (2008). A microRNA DNA methylation signature for human cancer metastasis. *Proc Natl Acad Sci U S A*, **105**, 13556-61.
- Luo FY, Xiao S, Liu ZH, et al (2015). Kank1 reexpression induced by 5-Aza-2'-deoxycytidine suppresses nasopharyngeal carcinoma cell proliferation and promotes apoptosis. *Int J Clin Exp Pathol*, **8**, 1658-65.
- McDermott AL, Dutt SN, Watkinson JC (2001). The aetiology of nasopharyngeal carcinoma. *Clin Otolaryngol Allied Sci*, **26**, 82-92.
- Mittag F, Kuester D, Vieth M, et al (2006). DAPK promoter methylation is an early event in colorectal carcinogenesis. *Cancer Lett*, **240**, 69-75.
- Mo Y, Midorikawa K, Zhang Z, et al (2012). Promoter hypermethylation of Ras-related GTPase gene RRAD inactivates a tumor suppressor function in nasopharyngeal carcinoma. *Cancer Lett*, **323**, 147-54.
- Nawaz I, Hu LF, Du ZM, et al (2015a). Integrin alpha9 gene promoter is hypermethylated and downregulated in nasopharyngeal carcinoma. *Oncotarget*, **6**, 31493-507.
- Nawaz I, Moumad K, Martorelli D, et al (2015b). Detection of nasopharyngeal carcinoma in Morocco (North Africa) using a multiplex methylation-specific PCR biomarker assay. *Clin Epigenetics*, **7**, 89.
- Peng D, Ren CP, Yi HM, et al (2006). Genetic and epigenetic alterations of DLC-1, a candidate tumor suppressor gene, in nasopharyngeal carcinoma. *Acta Biochim Biophys Sin (Shanghai)*, **38**, 349-55.
- Ramos EA, Camargo AA, Braun K, et al (2010). Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer. *BMC Cancer*, **10**, 23.
- Ran Y, Wu S, You Y (2011). Demethylation of E-cadherin gene in nasopharyngeal carcinoma could serve as a potential therapeutic strategy. *J Biochem*, **149**, 49-54.
- Razak AR, Siu LL, Liu FF, et al (2010). Nasopharyngeal

- carcinoma: the next challenges. *Eur J Cancer*, **46**, 1967-78.
- Seng TJ, Low JS, Li H, et al (2007). The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. *Oncogene*, **26**, 934-44.
- Shu XS, Li L, Ji M, et al (2013). FEZF2, a novel 3p14 tumor suppressor gene, represses oncogene EZH2 and MDM2 expression and is frequently methylated in nasopharyngeal carcinoma. *Carcinogenesis*, **34**, 1984-93.
- Sun D, Zhang Z, Van do N, et al (2007). Aberrant methylation of CDH13 gene in nasopharyngeal carcinoma could serve as a potential diagnostic biomarker. *Oral Oncol*, **43**, 82-7.
- Sung FL, Cui Y, Hui EP, et al (2014). Silencing of hypoxia-inducible tumor suppressor lysyl oxidase gene by promoter methylation activates carbonic anhydrase IX in nasopharyngeal carcinoma. *Am J Cancer Res*, **4**, 789-800.
- Tao Q, Chan AT (2007). Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. *Expert Rev Mol Med*, **9**, 1-24.
- Tian F, Yip SP, Kwong DL, et al (2013). Promoter hypermethylation of tumor suppressor genes in serum as potential biomarker for the diagnosis of nasopharyngeal carcinoma. *Cancer Epidemiol*, **37**, 708-13.
- Tong JH, Ng DC, Chau SL, et al (2010). Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. *BMC Cancer*, **10**, 253.
- Tong JH, Tsang RK, Lo KW, et al (2002). Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma. *Clin Cancer Res*, **8**, 2612-9.
- Tsao SW, Liu Y, Wang X, et al (2003). The association of E-cadherin expression and the methylation status of the E-cadherin gene in nasopharyngeal carcinoma cells. *Eur J Cancer*, **39**, 524-31.
- Wang S, Xiao X, Zhou X, et al (2010). TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma. *BMC Cancer*, **10**, 617.
- Wang S, Zhang R, Claret FX, et al (2014). Involvement of microRNA-24 and DNA methylation in resistance of nasopharyngeal carcinoma to ionizing radiation. *Mol Cancer Ther*, **13**, 3163-74.
- Wei WI, Sham JS (2005). Nasopharyngeal carcinoma. *Lancet*, **365**, 2041-54.
- Wong AM, Kong KL, Chen L, et al (2013). Characterization of CACNA2D3 as a putative tumor suppressor gene in the development and progression of nasopharyngeal carcinoma. *Int J Cancer*, **133**, 2284-95.
- Wong TS, Chang HW, Tang KC, et al (2002). High frequency of promoter hypermethylation of the death-associated protein-kinase gene in nasopharyngeal carcinoma and its detection in the peripheral blood of patients. *Clin Cancer Res*, **8**, 433-7.
- Wong TS, Kwong DL, Sham JS, et al (2003a). Promoter hypermethylation of high-in-normal 1 gene in primary nasopharyngeal carcinoma. *Clin Cancer Res*, **9**, 3042-6.
- Wong TS, Kwong DL, Sham JS, et al (2004). Quantitative plasma hypermethylated DNA markers of undifferentiated nasopharyngeal carcinoma. *Clin Cancer Res*, **10**, 2401-6.
- Wong TS, Tang KC, Kwong DL, et al (2003b). Differential gene methylation in undifferentiated nasopharyngeal carcinoma. *Int J Oncol*, **22**, 869-74.
- Xiao X, Zhao W, Tian F, et al (2014). Cytochrome b5 reductase 2 is a novel candidate tumor suppressor gene frequently inactivated by promoter hypermethylation in human nasopharyngeal carcinoma. *Tumour Biol*, **35**, 3755-63.
- Yanatsaneejit P, Chalermchai T, Kerekhanjanarong V, et al (2008). Promoter hypermethylation of CCNA1, RARRES1, and HRASLS3 in nasopharyngeal carcinoma. *Oral Oncol*, **44**, 400-6.
- Yang X, Dai W, Kwong DL, et al (2015). Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting. *Int J Cancer*, **136**, 127-35.
- Yang Z, Lan H, Chen X, et al (2014). Molecular alterations of the WWOX gene in nasopharyngeal carcinoma. *Neoplasma*, **61**, 170-6.
- Yi B, Tan SX, Tang CE, et al (2009). Inactivation of 14-3-3 sigma by promoter methylation correlates with metastasis in nasopharyngeal carcinoma. *J Cell Biochem*, **106**, 858-66.
- Yi HM, Li H, Peng D, et al (2006). Genetic and epigenetic alterations of LTF at 3p21.3 in nasopharyngeal carcinoma. *Oncol Res*, **16**, 261-72.
- Ying J, Li H, Seng TJ, et al (2006). Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. *Oncogene*, **25**, 1070-80.
- Ying J, Srivastava G, Hsieh WS, et al (2005). The stress-responsive gene GADD45G is a functional tumor suppressor, with its response to environmental stresses frequently disrupted epigenetically in multiple tumors. *Clin Cancer Res*, **11**, 6442-9.
- You Y, Ma L, You M, et al (2010). TSLC1 gene silencing in cutaneous melanoma. *Melanoma Res*, **20**, 179-83.
- You Y, Yang W, Qin X, et al (2015). ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma. *Cell Oncol*, **38**, 205-14.
- You Y, Yang W, Wang Z, et al (2013). Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas. *Cell Oncol*, **36**, 323-31.
- Zhang H, Feng X, Liu W, et al (2011). Underlying mechanisms for LTF inactivation and its functional analysis in nasopharyngeal carcinoma cell lines. *J Cell Biochem*, **112**, 1832-43.
- Zhang S, Li S, Gao JL (2013). Promoter methylation status of the tumor suppressor gene SOX11 is associated with cell growth and invasion in nasopharyngeal carcinoma. *Cancer Cell Int*, **13**, 109.
- Zhou W, Feng X, Li H, et al (2009). Inactivation of LARS2, located at the commonly deleted region 3p21.3, by both epigenetic and genetic mechanisms in nasopharyngeal carcinoma. *Acta Biochim Biophys Sin*, **41**, 54-62.